BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, July 5, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for May 29, 2024

May 29, 2024
Biopharmas raising money in public or private financings, including: Adcendo, Avelos, Cytokinetics, Expressionedits, Gameto, Insmed, Lambdavision, Matter Bio, Merus.
Read More

Financings for May 29, 2024

May 29, 2024
Med-tech firms raising money in public or private financings, including: Boryung, Lambdavision.
Read More

Financings for May 28, 2024

May 28, 2024
Biopharmas raising money in public or private financings, including: Actuate, Boost, Dyne, Enlivex, Genelux, Lucy, Reviva.
Read More

Financings for May 28, 2024

May 28, 2024
Med-tech firms raising money in public or private financings, including: Venus Concept.
Read More

Financings for May 24, 2024

May 24, 2024
Biopharmas raising money in public or private financings, including: Virios, Xgen.
Read More

Financings for May 24, 2024

May 24, 2024
Med-tech firms raising money in public or private financings, including: Royal Philips.
Read More
AI dollar sign
Med-tech financings 1Q24

Med-tech sector optimistic as financings reach $6.38B in Q1

May 24, 2024
By Amanda Lanier
The med-tech sector experienced some relief in the first quarter of 2024 (1Q24) as total financings climbed to $6.38 billion, eclipsing the value of any quarter in 2023. For perspective, the final quarter of 2023 recorded $3.32 billion, and 1Q23 raised $4.69 billion, with an average of $4.42 billion in financings per quarter in 2023.
Read More

Promising data help Grey Wolf land $50M series B expansion

May 23, 2024
By Nuala Moran
Grey Wolf Therapeutics Ltd. added $50 million to its series B, bringing the total for the round to $99 million and providing funding to expand the scope of an ongoing phase I/II trial of its lead antigen modulation program.
Read More

Financings for May 23, 2024

May 23, 2024
Biopharmas raising money in public or private financings, including: Bicycle, Cytokinetics, Foghorn, Radar, Rakovina.
Read More

Financings for May 23, 2024

May 23, 2024
Med-tech firms raising money in public or private financings, including: Allez, Haemonetics.
Read More
Previous 1 2 … 197 198 199 200 201 202 203 204 205 … 681 682 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2026.
  • AI-generated image for brain organoid neural research

    CINP 2026: organoids reveal autism and addiction mechanisms

    BioWorld Science
    At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
  • Ontrack Therapeutics divulges compounds for neurodegenerative diseases

    BioWorld Science
    Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
  • CINP 2026: Prenatal and adolescent stress shape brain vulnerability

    BioWorld Science
    Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
  • Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists

    BioWorld Science
    Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing